Skip to main content

ORAGENICS INC

For the period ended Dec 31, 2025. Filed Mar 16, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 16, 2026

OGEN$0.34-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 8. CONSOLIDATED STATEMENTS OF CASH FLOWS

Year Ended December 31,
20252024
Cash flows from operating activities:
Net loss$(9,842,487)$(10,567,918)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and closing costs771,437-
Stock-based compensation expense642,364516,049
Stock-based compensation recapture expense(86,617)-
Common stock for services rendered126,140-
Changes in operating assets and liabilities:
Other receivables(53,082)-
Prepaid expenses and other current assets(1,007,286)1,574,287
Operating lease right of use assets-9,811
Accounts payable and accrued expenses203,144(119,800)
Change in operating lease liabilities-(9,811)
Net cash used in operating activities(9,246,387)(8,597,382)
Cash flows from financing activities:
Borrowings on short-term notes payable2,455,911-
Payments on short-term notes payable(3,328,528)(693,109)
Net proceeds from issuance of preferred stock and warrants15,019,700-
Net proceeds from issuance of common stock2,634,1906,671,830
Net cash provided by financing activities16,781,2735,978,721
Net increase (decrease) in cash and cash equivalents7,534,886(2,618,661)
Cash and cash equivalents at beginning of period864,8403,483,501
Cash and cash equivalents at end of year$8,399,726$864,840
Supplemental disclosure of cash flow information:
Interest paid$22,353$29,828
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.